{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-22-000448","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2022-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.262408+00:00","generated_at":"2026-06-23T05:21:56.931150+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioVie reports 82% responder rate in Phase 2 Alzheimer's study; Phase 3 on track for mid-2023 readout","bullets":["82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).","Phase 3 NE3107 Alzheimer's trial has enrolled >50% of 316 patients; topline data expected mid-2023.","Phase 2 Parkinson's NE3107 trial expected to read out by end of 2022; early blinded data consistent with animal studies.","Phase 2b BIV201 ascites trial enrollment slowed by COVID; topline data now expected mid-2023.","Full data from exploratory Alzheimer's study to be presented at CTAD conference Nov 29–Dec 2, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-22-000448","json":"https://secwatch.observer/filing/0001520138-22-000448.json","markdown":"https://secwatch.observer/filing/0001520138-22-000448.md","text":"https://secwatch.observer/filing/0001520138-22-000448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/0001520138-22-000448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/bivi-20221004_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:21:56.931150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}